[F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation
What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.
1. A compound of the formula:
2. A process for preparing the compound according to claim 1 , said process comprising:
removing one or more protective groups present in a compound of the formula (II)
Q represents
a) N(H)-tert-butoxycarbonyl,
b) N(H)-allyloxycarbonyl,
c) N(H)-benzyloxycarbonyl,
d) N(H)-ethoxycarbonyl,
e) N(H)-methoxycarbonyl,
f) N(H)-propoxycarbonyl,
g) N(H)-2,2,2-trichloroethoxycarbonyl,
h) N(H)-1,1-dimethylpropynyl,
i) N(H)-1-methyl-1-phenylethoxycarbonyl,
j) N(H)-1-methyl-1-(4-biphenylyl)ethoxycarbonyl,
k) N(H)-cyclobutylcarbonyl,
l) N(H)-1-methylcyclobutylcarbonyl,
m) N(H)-vinylcarbonyl,
n) N(H)-allylcarbonyl,
o) N(H)-adamantylcarbonyl,
p) N(H)-diphenylmethylcarbonyl,
q) N(H)-cinnamylcarbonyl,
r) N(H)-formyl,
s) N(H)-benzoyl,
t) N(H)-trityl,
u) N(H)-p-methoxydiphenylmethyl,
v) N(H)-di(p-methoxyphenyl)phenylmethyl,
or
x) N-(tert-butoxycarbonyl) 2 ,
in which
X′ and X″ independently of one another represent
a) branched or straight-chain C 1 -C 5 alkyl,
b) substituted or unsubstituted aryl,
c) substituted or unsubstituted aralkyl or
d) substituted or unsubstituted heteroaryl.
3. A method of imaging a patient for tumor disorders comprising imaging a patient who has been administered a compound according to claim 1 .
4. An imaging kit, comprising a compound according to claim 1 .
5. A pharmaceutical composition, comprising a compound according to claim 1 and a suitable pharmaceutical carrier substance.
6. A compound according to claim 1 , suitable for imaging in a dosage range of 37-600 MBq.
7. The compound according to claim 6 , suitable for imaging in a dosage range of 150 MBq-370 MBq.